UEG Week: Teva and Sanofi's Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn's Disease
Teva Pharmaceuticals and Sanofi presented positive 44-week data from the RELIEVE UCCD phase 2b study, showing duvakitug maintained efficacy in ulcerative colitis (UC) and Crohn's disease (CD). The drug achieved high rates of clinical remission, response, and endoscopic improvement. Duvakitug was well-tolerated, with a safety profile consistent with the induction phase. The companies are advancing duvakitug in phase 3 trials for UC and CD, and a phase 2 study for hidradenitis suppurativa.
How this was made
The 30-second read
Why it matters
Positive trial outcomes could catalyze share price moves for both Teva and Sanofi, and influence investor sentiment in the IBD biotech space.
Market read
First report of material clinical data for a late‑stage IBD drug, likely to affect biotech valuations and sector sentiment.
What to watch
Regulatory approval timelines and competition from other IBD therapies could temper upside.
Background
The article reports first‑time disclosure of duvakitug Phase 2b long‑term extension results presented at UEG Week 2026.
Ticker impact
Teva announced positive Phase 2b long-term extension data for duvakitug in ulcerative colitis and Crohn's disease.
likely upward pressure as market prices in the encouraging trial results.
Phase 2b data are material for biotech stocks; the study shows high remission rates and a clean safety profile.
Sanofi co‑developed duvakitug and presented the same positive Phase 2b data at UEG Week.
moderate upside as investors reassess Sanofi's pipeline prospects.
Sanofi's involvement in a successful trial enhances its biotech pipeline narrative.
Market effects
Strengthens the IBD therapeutic sector and may lift peer biotech stocks.
Positive for US and European biotech markets where both firms are listed.
Adds optimism to global drug development pipelines targeting inflammatory diseases.
Counterpoint
Skeptics may argue that Phase 2b data do not guarantee Phase 3 success or commercial viability.
Key entities
- companyTeva Pharmaceuticals
US‑listed pharmaceutical company (ticker TEVA) co‑developer of duvakitug.
- companySanofi
US‑listed pharmaceutical company (ticker SNY) co‑developer of duvakitug.
